SENTIS™ Homologous Recombination Deficiency (HRD) test expands potential population that can possibly benefit from PARP inhibitors treatments  through assessing genomic instability indicators in cancer cells. Using SNP array method, the panel detects HRD indicators variation including telomere allelic imbalance (TAI), loss of heterozygosity (LOH) and large-scale state transition (LST), and bioinformatics analysis is performed based on BGI database.